Fool - Investing News·1 day ago
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Teva Pharmaceutical Industries Limited(TEVA)Earnings, Financials & Key Ratios
TEVA•NYSE
$33.44
27.9× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.Show more
- Revenue$17.26B+4.3%
- EBITDA$3.16B+317.9%
- Net Income$1.41B+186.0%
- EPS (Diluted)1.20+182.8%
- Gross Margin51.79%+6.3%
- EBITDA Margin18.31%+300.6%
- Operating Margin12.5%+782.5%
- Net Margin8.17%+182.5%
- ROE20.68%+187.4%
TEVA Price & Volume
Teva Pharmaceutical Industries Limited (TEVA) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Persistent Debt Fragility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Strained
Cash Flow:Mixed
Primary Risk:High Debt Refinancing Burden
Key Thesis Takeaways
- Teva's investment outlook remains constrained by significant structural volatility, as the company navigates a complex transition between legacy generic pricing pressures and the scaling of specialty assets like Austedo.
- While management has successfully reduced total debt from $20.2 billion in 2023Q4 to $16.9 billion in 2026Q1, the persistent $13.4 billion negative retained earnings balance and high goodwill exposure of $15.8 billion continue to weigh on the long-term equity profile.
- Investors should monitor the company's ability to maintain consistent operating margins, which have fluctuated between -5.7% and 19.7% over the last ten quarters, before assuming a sustainable recovery in shareholder value.
Verdict Logic
while the company has reduced its debt-to-equity ratio from 3.16 in 2024Q4 to 2.05 in 2026Q1, the ongoing volatility in operating income and the $15.8 billion goodwill burden warrant a cautious wait-and-see approach.
TEVA Growth Metrics
Teva Pharmaceutical Industries Limited (TEVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.29%
5 Years0.71%
3 Years4.96%
TTM4.41%
Profit CAGR
10 Years-1.18%
5 Years-
3 Years-
TTM221.62%
EPS CAGR
10 Years-4.08%
5 Years-
3 Years-
TTM216.67%
Return on Capital
10 Years-3.03%
5 Years1.32%
3 Years2.77%
Last Year8.02%
TEVA Recent Earnings
Teva Pharmaceutical Industries Limited (TEVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.53+6.0%
$0.50
Rev
$4.0B+5.1%
$3.8B
Q1 2026
Jan 28, 2026Metric
Actual
Est
EPS
$0.96+47.7%
$0.65
Rev
$4.7B+9.1%
$4.3B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.78+14.7%
$0.68
Rev
$4.5B+0.6%
$4.5B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.66+4.8%
$0.63
Rev
$4.2B-4.3%
$4.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.53vs $0.50+6.0% | $4.0Bvs $3.8B+5.1% |
| Q1 2026 | Jan 28, 2026 | $0.96vs $0.65+47.7% | $4.7Bvs $4.3B+9.1% |
| Q4 2025 | Nov 5, 2025 | $0.78vs $0.68+14.7% | $4.5Bvs $4.5B+0.6% |
| Q3 2025 | Jul 30, 2025 | $0.66vs $0.63+4.8% | $4.2Bvs $4.4B-4.3% |
Based on last 12 quarters of dataView full earnings history →
Latest TEVA News
Recent stock market news and headlines for Teva Pharmaceutical Industries Limited (TEVA)
Fool - Investing News·5 days ago
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
Zacks Investment Research·Jun 23, 2026
Teva's Shift Beyond Generics Puts Focus on Branded Drug GrowthTEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.
Zacks Investment Research·Jun 19, 2026
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette SyndromeTEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.
The Motley Fool·Jun 19, 2026
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.
Peers Comparison
Key metrics vs top competitors for Teva Pharmaceutical Industries Limited (TEVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.44 | $38.94B | 27.87 | 4.31% | 8.17% | 20.68% | — | |
| $16.96 | $19.75B | -5.65 | -2.98% | -2.04% | -1.97% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $17.05 | $5.44B | 77.50 | 8.05% | 4.02% | — | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — |
Compare TEVA vs Peers
Teva Pharmaceutical Industries Limited (TEVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TEVA SEC Filings & Documents
Teva Pharmaceutical Industries Limited (TEVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Jan 28, 2026·SEC
Material company update
Jan 12, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when TEVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TEVA Frequently Asked Questions
Teva Pharmaceutical Industries Limited (TEVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Teva Pharmaceutical Industries Limited's revenue?
Teva Pharmaceutical Industries Limited (TEVA) reported $17.35B in revenue for fiscal year 2025. This represents a 1719% increase from $953.8M in 1996.
How fast is Teva Pharmaceutical Industries Limited growing?
Teva Pharmaceutical Industries Limited (TEVA) grew revenue by 4.3% over the past year. Growth has been modest.
Is TEVA profitable?
Yes, Teva Pharmaceutical Industries Limited (TEVA) is profitable, generating $1.56B in net income for fiscal year 2025 (8.2% net margin).
Dividend & Returns
What is TEVA's return on equity?
Teva Pharmaceutical Industries Limited (TEVA) has a return on equity (ROE) of 20.7%. This is excellent, indicating efficient use of shareholder capital.
What is Teva Pharmaceutical Industries Limited's free cash flow?
Teva Pharmaceutical Industries Limited (TEVA) generated $1.17B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.